Generex Biotechnology Corporation RNAi-Based Tumor Vaccine Set for Trials in China to be Presented At Leading International Oncology Meeting

WORCESTER, Mass., Oct. 9, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today that Dr. Minzhen Xu, Vice President of Biology at Antigen Express, Inc., the Company's immunotherapy subsidiary, will make a presentation at a scientific symposium on the Company's strategy for converting cancer cells into potent tumor vaccine cells